1st Quarter - Report

THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION

Firm
Client
Income
—
Expenses
$120,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Advise on standards setting verification, overseas programs, and quality medicines - activities related to drugs, dietary supplements, food ingredients, and compounding HR 934, Personal Drug Importation Fairness Act of 2017; provisions related to importation. HR 1020, Compassionate Freedom of Choice Act of 2017; provisions related to importation. S 92/S 64, Safe and Affordable Drugs from Canada Act of 2017; provisions related to importation. S 183, Short on Competition Act; provisions related to importation. S. 469, the Affordable and Safe Prescription Drug Importation Act; provisions related to importation. Medication adherence HR 592/S 109, Pharmacy and Medically Underserved Areas Enhancement Act; provisions related to provider status. User fee agreements HR 749, Lower Drug Costs Through Competition Act; provisions related to generic competition

LobbyistCovered position, as disclosed
CARRIE HARNEY New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 749 (115th), S. 469 (115th), H.R. 1020 (115th), H.R. 934 (115th), H.R. 592 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.